



# Survival and prognostic factors in primary vaginal cancer: an analysis of 2004–2014 SEER data

Jianqin Huang<sup>1#</sup>, Meiyu Cai<sup>2#</sup>, Zhiling Zhu<sup>1</sup>

<sup>1</sup>Department of Integrative Medicine, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China; <sup>2</sup>Department of Quality Management, Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China

*Contributions:* (I) Conception and design: Z Zhu; (II) Administrative support: Z Zhu; (III) Provision of study materials or patients: J Huang, M Cai; (IV) Collection and assembly of data: J Huang; (V) Data analysis and interpretation: J Huang, M Cai; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work.

*Correspondence to:* Zhiling Zhu, Department of Integrative Medicine, Obstetrics and Gynecology Hospital, Fudan University, 128 Shenyang Road, Yangpu District, Shanghai 200090, China. Email: zhilingzhu888@126.com.

**Background:** Primary vaginal cancer (PVC) is a rare gynecological malignant tumor and we know little about its survival and prognostic factors. The purpose of this study is to evaluate the potential survival and prognostic factors in women with PVC.

**Methods:** We used data from the Surveillance, Epidemiology, and End Results (SEER) program to identify 1,781 women who had been diagnosed with PVC between 2004 and 2014. Univariate and multivariable analyses were used to evaluate cases survival and prognostic factors. A stratified analysis was further performed to analyze the prognostic factors in each stage.

**Results:** There were 20.0% of patients aged  $\geq 80$  years and most women were married, 42.1%, and then widowed, 25.2%. The histology types include squamous (74.5%), adenocarcinoma (16.7%), melanoma (3.3%) and sarcoma (1.5%). Five-year cause-specific survival (CSS) rates were overall: 57.8%, Stage I: 76.4%, Stage II: 61.9%, Stage III: 53.3% and Stage IV: 22.5%. Univariate analysis showed that age, marital status, race, pathological grading, histology, TNM stage, tumor size, surgery and radiation were related to prognosis. The 5-year CSS of married women is 64.4%, while those of divorced/separated and widowed are 56.6% and 44.1%, respectively. Multivariate analysis indicated that age, histology, TNM stage, tumor size, surgery and radiation were independent prognostic factors. The elderly ( $\geq 80$ ) cases and those with melanoma were correlated to worse prognosis at any stage of PVC. As tumor stage progressed, both of the  $\geq 80$  years old patients and the melanoma cases showed a decline tendency of mortality risk.

**Conclusions:** PVC is a rare gynecological malignant tumor and more likely to occur among older women. Squamous cell carcinoma is the most frequently observed histological type, while melanoma is extremely rare. Age, histology, TNM stage, tumor size, surgery and radiation are independent prognostic factors. Although marital status does not affect survival rates, married women are likely to live longer than widowed and divorced/separated cases. Age  $\geq 80$  years seems to be an important cut point in the survival of vaginal cancer. Older age ( $\geq 80$  years) and melanoma have greater influences on mortality risk in early-stage disease.

**Keywords:** Survival; prognostic factors; primary vaginal cancer (PVC); Surveillance, Epidemiology, and End Results (SEER)

Submitted Apr 14, 2020. Accepted for publication Sep 14, 2020.

doi: 10.21037/tcr-20-1825

View this article at: <http://dx.doi.org/10.21037/tcr-20-1825>

## Introduction

Primary vaginal cancer (PVC) is a rare malignancy, approximately accounting for 1% to 3% of all gynecologic malignancies (1). In the United States, only 4,620 new cases of vaginal cancer were expected to occur in 2016, while 950 patients were expected to die from it (2). And an estimated 4,810 new cases of PVC, and an estimated 1,240 PVC deaths, occurred in 2017 (3). Due to the rarity of this disease, there is still minimal information on its epidemiology, treatment, survival, and prognostic factors. PVC is predominantly a disease of older women and it is most frequently diagnosed in the sixth or seventh decade of life (4). The main pathological types of PVC are squamous cell carcinoma (SCC, 79–85% of cases), adenocarcinoma (5–14%) (5), melanoma (1–5%) (6) and sarcoma. PVC is thought to share many of the same risk factors as cervical cancer, such as tobacco use, younger age at coitarche, human papillomavirus (HPV) infection, multiple sexual partners and long-term mucosal irritation or injury such as by prolonged pessary usage (7,8). At present, no standardized treatment for this rare cancer is available. Surgery and radiation are the main treatments for vaginal cancer (9,10). Previous studies have indicated that the dominant prognostic factors for PVC include age, histological type, grade of differentiation, stage, tumor size, tumor site, surgery, radiation and chemotherapy (5,11–15). Although some recent studies have shown marital status to be an independent predictor of survival in various gynecologic cancers, with married women enjoying longer survival and lower mortality than widows and single women (16–19), the effect of marital status on PVC prognosis had not, to our knowledge, been specially studied.

The SEER database currently includes patient data from 17 population-based cancer registries (26% of the United States population). We therefore utilized this large population-based database to analyze survival and prognostic factors in PVC, and to evaluate clinical characteristics, including marital status, on mortality among women with PVC. Because staging likely affects relationships between clinical characteristics and mortality risk, we performed a stratified analysis to elucidate prognostic factors at each stage. We present the following article in accordance with the STROBE reporting checklist (available at <http://dx.doi.org/10.21037/tcr-20-1825>).

## Methods

### *Data extraction*

Women diagnosed with PVC between 2004 and 2014 were identified through the National Cancer Institute's SEER Program. The data had been authorized by SEER database and ethical review was not required. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). We excluded patients who (I) were younger than 18 years at diagnosis; (II) had carcinoma in situ; (III) had another primary cancer at diagnosis, but the vaginal cancer was not the first one; or (IV) had no available data on TNM stage, survival, or marital status. The survival time was calculated on a monthly basis, starting from the diagnosis time of the patient, and ending on the day of death, loss to follow up or the follow-up deadline. The last follow-up date was December 31, 2014. The patients were followed up for 0–131 months, with a median follow-up time of 25 months. No patients were lost. A total of 1,781 eligible women with PVC were identified using SEER\*Stat 8.3.5.

### *Statistical analysis*

The primary outcome of interest in this study was cause-specific mortality. Clinical characteristics were summarized using frequency and percentage for categorical covariates. Categorical and continuous variables were compared using Fisher's exact test and Wilcoxon rank-sum test, respectively. Survival curves were generated using the Kaplan-Meier method. Statistical significance was assessed with the log rank  $\chi^2$  test. The associations between vaginal cancer mortality risk within categories of year of diagnosis (5-year intervals: 2004–2008, 2009–2014), age at diagnosis (18–49, 50–69, 70–79,  $\geq 80$ ), marital status (single, married, divorced/separated, widowed), race (white, black, other, unknown), pathological grading (I, II, III, IV, Unknown), histotype (SCC, adenocarcinoma, melanoma, sarcoma, other), TNM stage (I, II, III, IV), tumor size (<4 cm,  $\geq 4.0$  cm, unknown), surgery (yes, no, unknown), and radiation (yes, no) were estimated using Cox regression models. Multivariate adjusted hazard ratios (HR) and their associated 95% confidence intervals (CI) were calculated as estimates of relative mortality risk. As stage is a likely modifier of the relationships between clinical characteristics and mortality

risk, we stratified our assessments of the effects of clinical characteristics by stage and P values for interactions that were calculated based on likelihood ratio testing. Analyses were performed using SAS version 9.4 (SAS Institute, INC, Cary, NC, USA), and figures were graphed using GraphPad Prism 8 (GraphPad Software, LLC, San Diego, USA). P values were two-sided.  $P < 0.05$  was considered significant.

## Results

Among the 1,781 patients, 14.6% were aged 18–49 years at the time of diagnosis, and 20.0% aged  $\geq 80$  years; 42.1% were married, and 25.2% were widowed; 78.4% were Caucasian and 14.9% were African-American. The histologies were 74.5% SCC, 16.7% adenocarcinoma, 3.3% melanoma and 1.5% sarcoma; disease stages were stage I: 32.8%, stage II: 27.1%, stage III: 20.0%, and stage IV: 20.5%. Among treatments, 35.6% of patients underwent surgery and 74.8% received radiation (*Table 1*).

Based on Kaplan–Meier curves by stage, 5-year CSS rates were entire cohort: 57.8%, stage I: 76.4%, stage II: 61.9%, stage III: 53.3%, and stage IV: 22.5% (*Figure 1*). Univariate cox analysis showed that age, marital status, race, pathological grading, histology, TNM stage, tumor size, surgery and radiation were related to prognosis (*Figure 2*). Five-year CSS gradually decreased as age increased (18–49 years: 66.6%, 50–69 years: 65.5%, 70–79 years: 50.0%,  $\geq 80$  years: 38.5%; 70–79 *vs.* 18–49 years: HR 1.73,  $P = 0.0001$ ;  $\geq 80$  *vs.* 18–49 years: HR 2.55,  $P < 0.0001$ ). The 5-year CSS of married women is 64.4%, while those of divorced/separated and widowed are 56.6% and 44.1%, respectively (divorced/separated *vs.* married: HR 1.27,  $P = 0.0469$ ; widowed *vs.* married: HR 1.81,  $P < 0.0001$ ). The 5-year CSS of white is 58.6%, while that of black is 51.7% (HR 1.25,  $P = 0.0386$ ). Five-year CSS rates by pathological grade were grade I: 61.7%, grade II: 61.0%, grade III: 55.1%, and grade IV: 36.2% (grade IV *vs.* grade I: HR 1.82,  $P = 0.0128$ ). Women with SCC had the highest 5-year CSS rate (63.6%), and those with melanoma had the lowest rate (19.2%; HR 2.70,  $P < 0.0001$ ). Five-year CSS was significantly better for women with tumors  $< 4$  cm (71.8%) than for women with larger tumors (45.4%; HR 2.49,  $P < 0.0001$ ); for patients who received no surgery (48.9%) than those who underwent surgery (72.1%; HR 0.43,  $P < 0.0001$ ); and for those who received no radiotherapy (52.5%) than those who underwent radiotherapy (59.4%; HR 0.69,  $P < 0.0001$ ; *Table 2*).

In multivariate analysis, age, histology, TNM stage, tumor size, surgery and radiation were independent prognostic factors. Women aged 18–49 years had lower mortality risks than women aged 70–79 years (HR: 1.48) and those aged  $\geq 80$  years (HR: 2.62). Women with SCC had lower mortality risks than women diagnosed with sarcoma (HR: 1.98) or melanoma (HR: 4.35). Not surprisingly, stage was strongly related to risk, as women with stage I disease had lower mortality risks than those with stage II (HR: 1.77), stage III (HR: 2.28) or stage IV disease (HR: 5.43). Women with tumors larger than 4 cm had elevated risks of death (HR 1.62). Treatment with surgery and radiation reduced the mortality risk (HRs: 0.46 and 0.52, respectively; *Table 2*).

We performed a stratified analysis to identify differences in prognostic factors in each stage (*Table 3*). Compared with women aged 18–49 years, those  $\geq 80$  years had higher risk of death at each stage (stage I: HR 3.62, stage II: HR 2.7, stage III: HR 2.86, stage IV: HR 2.47,  $P < 0.05$ ). Women with melanoma also had higher mortality risk by disease stage compared with SCC [stage I: HR 14.41, stage III: HR 3.54, stage IV: HR 2.02,  $P < 0.05$  (because only one melanoma patient had stage II disease, it was omitted from our analysis)]. As tumor stage progresses, its effects on mortality risk in patients aged  $\geq 80$  years and those diagnosed with melanoma tends to decline.

## Discussion

PVC is a rare gynecological malignancy. Only a few PVC retrospective studies have been published. However, clinical information including epidemiology, treatment, survival, and prognostic factors, is very limited.

Compared with cervical cancer, vaginal cancer is more likely to occur among older women (20). The median age for invasive cervical cancer was 47 years (21); whereas, the median age for invasive vaginal cancer was 68 years. And its incidence increases with age; about 50% of PVC diagnoses are reportedly made in patients aged  $\geq 70$  years, and 20% in patients older than 80 years (5), which were similar to our findings of about 40% of PVC diagnosed in women aged  $\geq 70$  years, and 20% in patients older than 80 years. SCC, the most common PVC histology, is reported to account for 79–85% of PVC and usually occurs in elderly women, followed by adenocarcinoma (5–14%) (5), and melanoma (1–5%) (6). The most common histology types in our study were SCC (74.5%), adenocarcinoma (16.7%), and melanoma (3.3%), which were consistent with previous


**Table 1** Demographic and clinicopathological characteristics

Variables	Number	%
Diagnosis year		
2004–2008	803	45.1
2009–2014	978	54.9
Age, years		
18–49	260	14.6
50–69	818	45.9
70–79	347	19.5
≥80	356	20.0
Race		
White	1,397	78.4
Other	114	6.4
Black	265	14.9
Unknown	5	0.3
Marital status		
Married	750	42.1
Separated/divorced	276	15.5
Single	307	17.2
Widowed	448	25.2
Pathological grading		
Grade I	136	7.6
Grade II	551	30.9
Grade III	562	31.6
Grade IV	50	2.8
Unknown	482	27.1
Histology		
Squamous cell carcinoma	1,326	74.5
Adenocarcinoma	298	16.7
Melanoma	58	3.3
Sarcoma	27	1.5
Other	72	4.0
TNM stage		
I	584	32.8
II	483	27.1
III	349	19.6
IV	365	20.5

**Table 1** (continued)

**Table 1** (continued)


Variables	Number	%
Tumor size		
Less than 4 cm	697	39.1
Greater than 4 cm	514	28.9
Unknown	570	32.0
Surgery		
Yes	634	35.6
No	1,133	63.6
Unknown	14	0.8
Radiation		
Yes	1,332	74.8
No	449	25.2



**Figure 1** Survival curves for 1,781 patients with PVC (CSS is abbreviation for cause-specific survival).

reports. The majority of vaginal cancer is stage I as has been previously described (5). It was also found in our study that 32.8% of patients were stage I, occupying the largest proportion.

Reports of 5-year survival rates for PVC vary from 24% to 77.3% (14,22,23). Prognosis correlates strongly with disease stage. Five-year survival in larger series range from 64% to 84% for stage I, 53–75% for stage II, 36–46% for stage III and 3–36% for stage IV (9,24,25). In our study, 5-year CSS for all patients was 57.8%, and 76.4% (stage I), 61.9% (stage II), 53.3% (stage III) and 22.5% (stage IV). Major predictors of clinical outcome could be



**Figure 2** Survival curves for patients with PVC in univariate analysis. Survival curves (A,B,C,D,E,F,G,H,I) represent age, marital status, race, pathological grading, histology, TNM stage, tumor size, surgery and radiation, respectively ( $P < 0.05$ ).

grouped as patients' factors (performance status, older age, tobacco use, comorbidities, HPV-status, race, status of uterus) (5,11,12,23,26-29); tumor factors (disease stage, tumor size, histological type, pelvic lymph node metastasis, tumor site, grade of differentiation) (5,12,14,23,26,27); and treatment parameters (lymphadenectomy, brachytherapy utilization, concurrent chemoradiotherapy, higher facility volume, surgery, radiation dose, chemotherapy status) (11,14,15,25,29,30). Based on our univariate analysis results, age, marital status, race, pathological grade, histology, TNM stage, tumor size, surgery and radiation were related to prognosis. Multivariate analysis suggested that age, histology, TNM stage, tumor size, surgery and radiation were independent prognostic factors.

Notably, our study confirms the results of various prior

reports that have evaluated prognostic factors for PVC, lending credence to our findings. Stage is recognized as the most important determinant of prognosis for patients with PVC (9,11,12,14,23,27). Higher stage may be associated with more comorbidities, or decreased odds of surgery or lower radiation dose, and would therefore lead to poorer survival. Hiniker *et al.* reported that stage was the single best indicator of prognosis (31). A recent study showed that not only overall survival (OS), but also disease-free survival (DFS) and CSS for each stage of PVC were significant correlated with stage (12). In our study, compared with women with stage I disease, patients with stage II, stage III and stage IV disease had elevated mortality risks (HR: 1.77, 2.28 and 5.43, respectively). Marital status is reported to be an independent prognostic factor for survival for

**Table 2** Univariate and multivariate survival analyses

Variables	5-year CSS	Univariate analysis		Multivariate analysis <sup>†</sup>	
		HR (95% CI)	P	HR (95% CI)	P
Diagnosis year					
2004–2008	57.9%	Reference		Reference	
2009–2014	57.5%	0.99 (0.85–1.17)	0.9369	0.85 (0.72–1.01)	0.0588
Age, years					
18–49	66.6%	Reference		Reference	
50–69	65.5%	1.12 (0.86–1.45)	0.4039	1.10 (0.84–1.43)	0.5011
70–79	50.0%	1.73 (1.30–2.29)	0.0001	1.48 (1.10–2.00)	0.0100
≥80	38.5%	2.55 (1.95–3.66)	<0.0001	2.62 (1.92–3.58)	<0.0001
Marital status					
Married	64.4%	Reference		Reference	
Single	60.6%	1.20 (0.95–1.51)	0.1232	1.05 (0.83–1.34)	0.6746
Divorced/separated	56.6%	1.27 (1.00–1.61)	0.0469	1.26 (0.99–1.61)	0.0595
Widowed	44.1%	1.81 (1.49–2.19)	<0.0001	1.02 (0.82–1.27)	0.8664
Race					
White	58.6%	Reference		Reference	
Black	51.7%	1.25 (1.01–1.54)	0.0386	1.23 (0.99–1.53)	0.0618
Other	61.3%	0.85 (0.61–1.19)	0.3404	0.81 (0.57–1.14)	0.2313
Unknown	75.0%	0.48 (0.07–3.41)	0.4626	0.51 (0.07–3.64)	0.5000
Pathological grading					
I	61.7%	Reference		Reference	
II	61.0%	0.97 (0.70–1.35)	0.8644	0.94 (0.67–1.30)	0.6920
III	55.1%	1.28 (0.93–1.76)	0.1260	1.02 (0.73–1.40)	0.9305
IV	36.2%	1.82 (1.82–2.91)	0.0128	1.00 (0.62–1.62)	0.9947
Unknown	58.6%	1.11 (0.80–1.53)	0.5408	0.76 (0.54–1.08)	0.1240
Histology					
Squamous cell carcinoma	63.6%	Reference		Reference	
Adenocarcinoma	59.3%	0.86 (0.69–1.08)	0.1925	1.00 (0.79–1.26)	0.9864
Melanoma	19.2%	2.70 (2.01–3.63)	<0.0001	4.35 (3.06–6.18)	<0.0001
Sarcoma	58.8%	1.19 (0.65–2.16)	0.5740	1.98 (1.06–3.72)	0.0331
Other	47.2%	1.26 (0.87–1.81)	0.2158	1.42 (0.97–2.10)	0.0740
TNM stage					
I	76.4%	Reference		Reference	
II	61.9%	1.74 (1.37–2.21)	<0.0001	1.77 (1.37–2.30)	<0.0001
III	53.3%	2.33 (1.81–2.09)	<0.0001	2.28 (1.74–2.99)	<0.0001
IV	22.5%	6.17 (4.93–7.73)	<0.0001	5.43 (4.24–6.96)	<0.0001

**Table 2** (continued)

Table 2 (continued)

Variables	5-year CSS	Univariate analysis		Multivariate analysis <sup>†</sup>	
		HR (95% CI)	P	HR (95% CI)	P
Tumor size					
Less than 4 cm	71.8%	Reference		Reference	
Greater than 4 cm	45.4%	2.49 (2.04–3.04)	<0.0001	1.62 (1.31–2.01)	<0.0001
Unknown	51.0%	2.14 (1.75–2.61)	<0.0001	1.60 (1.31–1.97)	<0.0001
Surgery					
No	48.9%	Reference		Reference	
Yes	72.1%	0.43 (0.36–0.51)	<0.0001	0.46 (0.38–0.57)	<0.0001
Unknown	60.6%	0.67 (0.25–1.80)	0.4296	0.66 (0.24–1.79)	0.4132
Radiation					
No	52.5%	Reference		Reference	
Yes	59.4%	0.69 (0.58–0.82)	<0.0001	0.52 (0.43–0.63)	<0.0001

<sup>†</sup>, model adjusted for year of diagnosis, marital status, race, tumor size, grade, surgery, and radiation.

Table 3 Univariate and multivariate analyses of survival by age, histology, and cancer stage

Variables	5-year CSS	Univariate analysis		Multivariate analysis <sup>†</sup>	
		HR (95% CI)	P	HR (95% CI)	P
Stage I					
Age, years					
18–49	84.5%	Reference		Reference	
50–69	83.1%	1.35 (0.73–2.51)	0.3415	1.46 (0.77–2.79)	0.2469
70–79	69.0%	2.46 (1.25–4.82)	0.0091	1.74 (0.83–3.63)	0.1418
≥80	57.6%	4.05 (2.15–7.62)	<0.0001	3.62 (1.72–7.63)	0.0007
Histology					
Squamous cell carcinoma	80.9%	Reference		Reference	
Adenocarcinoma	83.6%	0.91 (0.52–1.60)	0.7442	1.07 (0.59–1.92)	0.8337
Melanoma	25.4%	5.86 (3.75–9.14)	<0.0001	14.41 (7.30–28.42)	<0.0001
Sarcoma	86.7%	1.05 (0.33–3.33)	0.9402	2.54 (0.74–8.78)	0.1402
Other	62.7%	2.03 (0.97–4.23)	0.0593	2.86 (1.32–6.21)	0.0080
Stage II					
Age, years					
18–49	74.1%	Reference		Reference	
50–69	75.0%	1.18 (0.63–2.22)	0.5986	0.95 (0.50–1.82)	0.8746
70–79	50.6%	2.34 (1.22–4.48)	0.0105	1.95 (1.95–0.98)	0.0557
≥80	35.9%	3.92 (2.09–7.36)	<0.0001	2.70 (1.33–5.46)	0.0058

Table 3 (continued)

Table 3 (continued)

Variables	5-year CSS	Univariate analysis		Multivariate analysis <sup>†</sup>	
		HR (95% CI)	P	HR (95% CI)	P
Histology					
Squamous cell carcinoma	60.8%	Reference		Reference	
Adenocarcinoma	66.8%	0.89 (0.58–1.35)	0.5724	1.39 (0.89–2.19)	0.1503
Melanoma <sup>‡</sup>	100.0%	0	0.9933	0.00	0.9976
Sarcoma <sup>‡</sup>	100.0%	0	0.9798	0.00	0.9933
Other	61.8%	0.86 (0.35–2.10)	0.7373	1.52 (0.59–3.89)	0.3871
Stage III					
Age, years					
18–49	57.2%	Reference		Reference	
50–69	57.9%	1.00 (0.58–1.73)	0.9927	1.16 (0.65–2.07)	0.6106
70–79	55.6%	1.29 (0.69–2.38)	0.4265	1.35 (0.68–2.67)	0.3892
≥80	36.2%	2.32 (1.27–4.21)	0.0059	2.86 (1.43–5.72)	0.0030
Histology					
Squamous cell carcinoma	55.0%	Reference		Reference	
Adenocarcinoma	60.3%	0.90 (0.56–1.47)	0.6769	1.07 (0.62–1.84)	0.8082
Melanoma	18.2%	3.01 (1.56–5.79)	0.001	3.54 (1.51–8.26)	0.0035
Sarcoma	0.0%	3.77 (1.19–11.96)	0.0242	1.91 (0.50–7.34)	0.3453
Other	47.6%	0.94 (0.35–2.56)	0.9052	0.82 (0.28–2.38)	0.7168
Stage IV					
Age, years					
18–49	31.0%	Reference		Reference	
50–69	26.9%	0.98 (0.66–1.45)	0.9101	1.03 (0.68–1.56)	0.8746
70–79	18.4%	1.20 (0.77–1.86)	0.4148	1.22 (0.75–1.98)	0.4265
≥80	6.3%	2.04 (1.30–3.20)	0.0018	2.47 (1.45–4.22)	0.0009
Histology					
Squamous cell carcinoma	23.3%	Reference		Reference	
Adenocarcinoma	29.9%	0.68 (0.47–0.97)	0.0342	0.78 (0.53–1.14)	0.2000
Melanoma	0.0%	1.59 (0.86–2.94)	0.1356	2.02 (1.02–4.01)	0.0449
Sarcoma	17.1%	1.76 (0.72–4.29)	0.2155	2.53 (0.97–6.65)	0.0589
Other	12.9%	1.10 (0.64–1.90)	0.7319	1.36 (0.73–2.54)	0.3301

<sup>†</sup>, model adjusted for year of diagnosis, marital status, race, tumor size, grade, surgery, and radiation; <sup>‡</sup>, this cohort included 1 stage II melanoma case and 1 stage II sarcoma case; both of these patients were still alive at last follow-up.



various gynecologic cancers, including vulvar, cervical, uterine and ovarian cancers, with married women enjoying longer survival and lower mortality (16-19). The stress and loss of social support that may accompany the loss of a spouse, or lack of social support for widowed, single or divorced women seems very apparent, and may alter immune function and contribute to tumor progression and mortality (32). Marriage status may receive more psychosocial support than widowed status through the psychoimmunological pathway. Wu *et al.* showed that being widowed was associated with greater risk of vulvar cancer mortality than that of nonwidowed counterparts (16). Machida *et al.* indicated that single marital status was significantly associated with increased cumulative risk of all-cause mortality and infectious mortality compared with the married status in cervical cancer (17). In an analysis of epithelial ovarian cancer from 1988 to 2006, Mahdi *et al.* found that women who were unmarried (single, widowed and divorced) had more advanced stage and higher all-cause mortality than married women (18). Lowery, *et al.* in their study of uterine cancer from 1991 to 2010, showed that compared with married, single, and divorced status, widowed status was an independently significant adverse factor (19). In our univariate analysis, the 5-year CSS of married women is 64.4%, while those of divorced/separated and widowed are 56.6% and 44.1%, respectively (divorced/separated *vs.* married: HR 1.27,  $P=0.0469$ ; widowed *vs.* married: HR 1.81,  $P<0.0001$ ). Widowed and divorced/separated women are probably less likely to be in a sexual relationship that may delay the diagnosis of vaginal cancer, while postcoital bleeding is a typical early symptom. Also being widowed and divorced/separated may lead to heightened emotional stress that can stimulate sympathetic responses and impair immune response. To our knowledge, this is the first study to show that the widowed and divorced/separated patients with PVC have lower survival and greater risk of death than married patients. Although multivariate analysis does not show any significant finding, further studies are needed.

Larger primary tumor size was associated with higher incidence of local failure, thereby negatively affecting survival. In a multivariate analysis of PVC patients, Hellman *et al.* (33) reported that lesions larger than 4 cm is a poor prognostic factor (HR: 2.1). Similar results were also obtained by Wolfson *et al.* (13), although the cut-off was changed to 2 cm; they reported that 5-year OS in patients with tumors sized  $\leq 2$  *vs.*  $> 2$  cm were 79.2% *vs.* 66.1% in stage I ( $P=0.0187$ ) and 80.9% *vs.* 51.2% in stage

II ( $P=0.0369$ ). We got similar results when the cut-off was 5 cm, which is consistent with Lian *et al.* (14). Similarly, in our study, tumor size  $>4$  cm was associated with a 1.62-fold increase of mortality risk in multivariate analysis.

Currently, no consensus on standardized treatment for PVC is available. As vaginal cancer partially contains the same epithelium as cervical cancer, and they share many of the same exposures and risk factors, PVC has often been treated similarly to cervical cancer. In principle, the mainstay therapy for vaginal cancer is radiation therapy (9,15). However, surgery is also an option. If diagnosed and staged earlier, both surgical resection and radiation can be curative in vaginal cancer (9, 10). In the case of a stage I or II tumor in the upper vagina, radical or modified radical hysterectomy and pelvic lymphadenectomy are often selected, in combination with vaginectomy with sufficient margin (10). And it was reported that the prognosis was better for surgical therapy than for radiation therapy alone if the tumor was located in the upper one-third of the vagina in clinical stage I or II (22,34). For adenocarcinoma, which is usually resistant to radiotherapy, surgical treatment has been recommended (35). However, for most patients, especially with advanced disease and unresectable tumors, radiation plays a central role in PVC treatment (9,15). Our data suggest decreased mortality rates in women who undergo surgery or radiation (HR: 0.46 or 0.52, respectively).

Vaginal cancer is primarily a disease of elderly women. Camille *et al.* (27) indicated that age  $>60$  years was negatively associated with survival ( $P=0.0339$ ; HR: 2.162). Wu *et al.* (7) also found that 5-year relative survival rates were lower among older women than among younger women with the same disease stage, and 5-year relative survivals for all stages combined were 80.9%, 73.9% and 49.5% for years  $<50$ , 50–64 and  $>65$ , respectively. However, Prameela *et al.* (12) reported no significant difference in OS, DFS or CSS between younger and older age groups. Platta *et al.* (36) had also failed to document any impact for age on treatment results. In our study, multivariate analysis indicated that age was an independent prognostic factor. Compared with women aged 18–49 years, women aged 70–79 years and those aged  $\geq 80$  years had higher mortality risks (HR: 1.48 and 2.62, respectively). A stratified analysis of the effect of age on survival by disease stage showed that, although women aged  $\geq 80$  years had higher mortality risk than women aged 18–49 years, the difference in mortality risk by age tended to decrease as disease stage progressed. Age has a greater impact on survival in patients with

earlier-stage disease. Interestingly, 80 years seems to be an important age cut point. Ghia *et al.* (23) reported that age older than 80 years (HR: 1.78; P=0.04) was associated with worse OS in a retrospective analysis. This may be related to the high comorbidity and limited treatment among older women.

Several studies have shown SCC tumors in PVC to have a survival advantage (11), whereas melanomas have a poor prognosis (5,25). Although most literature reports 5-year OS for vaginal melanoma to be less than 20% (5,6), Chirag *et al.* reported it to be 70% (which is much higher than that in other studies), and that patients with vaginal melanoma had a 1.51-fold increased mortality risk compared with vaginal SCC (25). In our study, 5-year CSS rates were 63.6% and 19.2% for women with SCC and melanoma, respectively, with a relatively higher mortality risk for women with melanoma (HR: 4.35). A stratified analysis of the effect of histology on survival by disease stage showed that, although melanoma carried a higher mortality risk than did SCC, this effect tended to decline as tumor stage progressed. Histology type seems to have a greater impact on survival in earlier-stage disease. The poor prognosis has been attributed to a variety of factors, including the poor visibility of vaginal melanoma (especially from the relatively high rate of amelanotic tumors), and anatomical proximity to the vulvovaginal venous plexus, leading to difficulties in surgery and radiotherapy; these factors are more pronounced in advanced patients.

## Conclusions

In conclusion, PVC is a rare gynecological malignant tumor and more likely to occur among older women. SCC is the most histological type of PVC, whereas melanoma is extremely rare. Age, histology, TNM stage, tumor size, surgery and radiation are independent prognostic factors. Married individuals seem to enjoy longer survival and lower mortality compared with widowed and divorced/separated women. Age  $\geq 80$  years seems to be an important cut point in the survival of vaginal cancer. The elderly ( $\geq 80$ ) cases and those with melanoma were correlated to worse prognosis at any stage of PVC. Age  $\geq 80$  years and melanoma seem to have greater influences on mortality risk in patients with early-stage disease. However, we must acknowledge its limitations in our study. First, its retrospective design is a potential source of bias. Second, several covariates of interest are unavailable from the SEER database, including HPV, smoking, number of lifetime partners, radiotherapy

dose, surgical details, and data on chemotherapy, which have been associated with PVC incidence and survival. Therefore, large-scale, prospective studies are urgently needed.

## Acknowledgments

The authors acknowledge the efforts of the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER database. The interpretation and reporting of these data are the sole responsibility of the authors.

*Funding:* None.

## Footnote

*Reporting Checklist:* The authors have completed the STROBE reporting checklist. Available at <http://dx.doi.org/10.21037/tcr-20-1825>

*Peer Review File:* Available at <http://dx.doi.org/10.21037/tcr-20-1825>

*Conflicts of Interest:* All authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tcr-20-1825>). The authors have no conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The data had been authorized by SEER database and ethical review was not required. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Damast S, Takiar V, McCarthy S, et al. Treatment of

- early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. *Gynecol Oncol Rep* 2016;17:89-92.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30.
  3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin* 2017;67:7-30.
  4. Madsen BS, Jensen HL, van den Brule AJ, et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina—Population-based case-control study in Denmark. *Int J Cancer* 2008;122:2827-34.
  5. William T C, Phillips JL, Menck HR. The National Cancer Data Base Report on Cancer of the Vagina. American Cancer Society 1998;83:1033-40.
  6. Tasaka R, Fukuda T, Wada T, et al. A retrospective clinical analysis of 5 cases of vaginal melanoma. *Mol Clin Oncol* 2017;6:373-6.
  7. Wu X, Matanoski G, Chen VW, et al. Descriptive epidemiology of vaginal cancer incidence and survival by race, ethnicity, and age in the United States. *Cancer* 2008;113:2873-82.
  8. Akino N, Wada-Hiraie O, Matsumoto Y, et al. Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. *J Obstet Gynaecol Res* 2016;42:748-51.
  9. Frank SJ, Jhingran A, Levenback C, et al. Definitive radiation therapy for squamous cell carcinoma of the vagina. *Int J Radiat Oncol Biol Phys* 2005;62:138-47.
  10. Saito T, Tabata T, Ikushima H, et al. Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. *Int J Clin Oncol* 2018;23:201-34.
  11. Rajagopalan MS, Xu KM, Lin JF, et al. Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. *Gynecol Oncol* 2014;135:495-502.
  12. Prameela CG, Ravind R, Gurram BC, et al. Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. *J Obstet Gynaecol India* 2016;66:363-71.
  13. Wolfson AH, Reis IM, Portelance L, et al. Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. *Gynecol Oncol* 2016;141:255-9.
  14. Lian J, Dundas G, Carlone M, et al. Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. *Gynecol Oncol* 2008;111:298-306.
  15. Yagi A, Ueda Y, Kakuda M, et al. Descriptive epidemiological study of vaginal cancer using data from the Osaka Japan population-based cancer registry: Long-term analysis from a clinical viewpoint. *Medicine (Baltimore)* 2017;96:e7751.
  16. Wu SG, Lin QJ, Li FY, et al. Widowed status increases the risk of death in vulvar cancer. *Future Oncol* 2018;14:2589-98.
  17. Machida H, Eckhardt SE, Castaneda AV, et al. Single Marital Status and Infectious Mortality in Women With Cervical Cancer in the United States. *Int J Gynecol Cancer* 2017;27:1737-46.
  18. Mahdi H, Kumar S, Munkarah AR, et al. Prognostic impact of marital status on survival of women with epithelial ovarian cancer. *Psychooncology* 2013;22:83-8.
  19. Lowery WJ, Stany MP, Phippen NT, et al. Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: a Surveillance, Epidemiology and End Results study. *Gynecol Oncol* 2015;136:328-35.
  20. Hellman K, Silfverswärd C, Nilsson B, et al. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956-1996. *Int J Gynecol Cancer* 2004;14:491-501.
  21. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. *Lancet* 2007;369:1693-702.
  22. Tjalma WA, Monaghan JM, de Barros Lopes A, et al. The role of surgery in invasive squamous carcinoma of the vagina. *Gynecol Oncol* 2001;81:360-5.
  23. Ghia AJ, Gonzalez VJ, Tward JD, et al. Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. *Int J Gynecol Cancer* 2011;21:378-84.
  24. de Crevoisier R, Sanfilippo N, Gerbaulet A, et al. Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. *Radiother Oncol* 2007;85:362-70.
  25. Shah CA, Goff BA, Lowe K, et al. Factors affecting risk of mortality in women with vaginal cancer. *Obstet Gynecol* 2009;113:1038-45.
  26. Ikushima H, Wakatsuki M, Ariga T, et al. Radiotherapy for vaginal cancer: a multi-institutional survey study of the Japanese Radiation Oncology Study Group. *Int J Clin Oncol* 2018;23:314-20.
  27. Gunderson CC, Nugent EK, Yunker AC, et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. *J Low Genit Tract Dis*

- 2013;17:409-13.
28. Larsson GL, Helenius G, Andersson S, et al. Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma. *Gynecol Oncol* 2013;129:406-11.
  29. Mahdi H, Kumar S, Hanna RK, et al. Disparities in treatment and survival between African American and White women with vaginal cancer. *Gynecol Oncol* 2011;122:38-41.
  30. Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. *PLoS One* 2013;8:e65048.
  31. Hiniker SM, Roux A, Murphy JD, et al. Primary squamous cell carcinoma of the vagina: prognostic factors, treatment patterns, and outcomes. *Gynecol Oncol* 2013;131:380-5.
  32. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. *Nat Rev Cancer* 2006;6:240-8.
  33. Hellman K, Lundell M, Silfverswärd C, et al. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. *Int J Gynecol Cancer* 2006;16:1201-11.
  34. Tabata T, Takeshima N, Nishida H, et al. Treatment failure in vaginal cancer. *Gynecol Oncol* 2002;84:309-14.
  35. Adams TS, Cuello MA. Cancer of the vagina. *Int J Gynaecol Obstet* 2018;143 Suppl 2:14-21.
  36. Platta CS, Anderson B, Geye H, et al. Adjuvant and definitive radiation therapy for primary carcinoma of the vagina using brachytherapy and external beam radiation therapy. *J Contemp Brachytherapy* 2013;5:76-82.

**Cite this article as:** Huang J, Cai M, Zhu Z. Survival and prognostic factors in primary vaginal cancer: an analysis of 2004–2014 SEER data. *Transl Cancer Res* 2020;9(11):7091-7102. doi: 10.21037/tcr-20-1825